Shandong Weigao Blood Purification Products Past Earnings Performance
Past criteria checks 3/6
Shandong Weigao Blood Purification Products has been growing earnings at an average annual rate of 40.4%, while the Medical Equipment industry saw earnings declining at 3.6% annually. Revenues have been growing at an average rate of 3.1% per year. Shandong Weigao Blood Purification Products's return on equity is 8.6%, and it has net margins of 12.5%.
Key information
40.36%
Earnings growth rate
36.78%
EPS growth rate
| Medical Equipment Industry Growth | 15.97% |
| Revenue growth rate | 3.09% |
| Return on equity | 8.61% |
| Net Margin | 12.52% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Shandong Weigao Blood Purification Products makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,532 | 442 | 878 | 155 |
| 31 Dec 22 | 3,426 | 315 | 922 | 183 |
| 31 Dec 21 | 2,911 | 260 | 847 | 153 |
Quality Earnings: 603014 has high quality earnings.
Growing Profit Margin: 603014's current net profit margins (12.5%) are higher than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 603014's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 603014's past year earnings growth to its 5-year average.
Earnings vs Industry: 603014 earnings growth over the past year (40.4%) exceeded the Medical Equipment industry -3%.
Return on Equity
High ROE: 603014's Return on Equity (8.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 11:25 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shandong Weigao Blood Purification Products Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.